Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 2, 2013, Pages 233-241

  Jamison, Patricia M ^a   Noone, Anne Michelle ^a   Ries, Lynn A G ^a   Lee, Nancy C ^b   Edwards, Brenda K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CAUCASIAN; ENDOMETRIUM CANCER; FEMALE; GENDER; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; NEGRO; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE;

AFRICAN AMERICANS; AGED; CROSS-SECTIONAL STUDIES; ENDOMETRIAL NEOPLASMS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; INCIDENCE; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; SEER PROGRAM; TIME FACTORS; UNITED STATES; UTERINE NEOPLASMS;

EID: 84873344831     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0996     Document Type: Article

References (49)

1. American Cancer Society. Cancer facts & figures 2012. Atlanta, GA: American Cancer Society; 2012.
2. SEER Cancer Statistics Review, 1975-2008. In: Howlader N, Noone AM, Krapcho M, et al., editors. Available from: http://seer.cancer.gov/csr/1975- 2008/, based on November 2010 SEER data submission, postedto the SEERweb site, 2011. Bethesda, MD: National Cancer Institute; 2011.
3. Cook LS, Weiss NS, Doherty JA, Chen C. Endometrial cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. 3rd ed. New York City: Oxford University Press; 2006. p. 1027-43.
4. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19:3119-30.
5. Richardson LC, Thomas C, Bowman BA. Obesity and endometrial cancer: challenges for public health action. Womens Health 2009;5:595-7.
6. Sonoda Y, Barakat RR. Screening and the prevention of gynecologic cancer: endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2006;20:363-77.
7. Weiss JM, Saltzman BS, Doherty JA, Voigt LF, Chen C, Beresford SA, et al. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. Am J Epidemiol 2006;164:56-62.
8. Hill HA, Eley JW, Harlan LC, Greenberg RS, Barrett RJ, Chen VW. Racial differences in endometrial cancer survival: the black/white cancer survival study. Obstet Gynecol 1996;88:919-26.
9. Madison T, Schottenfeld D, James SA, Schwartz AG, Gruber SB. Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am J Public Health 2004;94:2104-11.
10. Duong LM, Wilson RJ, Ajani UA, Singh SD, Eheman CR. Trends in endometrial cancer incidence rates in the United States, 1999-2006. J Womens Health (Larchmt) 2011;20:1157-63.
11. Evans T, Sany O, Pearmain P, Ganesan R, Blann A, Sundar S. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer 2011;104:1505-10.
12. Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 2010;21:1851-6.
13. Whiteman MK, Hillis SD, Jamieson DJ, Morrow B, Podgornik MN, Brett KM, et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol 2008;198:34-7.
14. Keshavarz H, Hillis SD, Kieke BA, Marchbanks PA. Hysterectomy Surveillance-United States, 1994-1999. MMWRCDC Surveill Summ 2002; SS05:1-8.
15. Merrill RM, Layman AB, Oderda G, Asche C. Risk estimates of hysterectomy and selected conditions commonly treated with hysterectomy. Ann Epidemiol 2008;18:253-60.
16. Howard BV, Kuller L, Langer R, Manson JE, Allen C, Assaf A, et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation 2005;111:1462-70.
17. Kjerulff KH, Guzinski GM, Langenberg PW, Stolley PD, Moye NE, Kazandjian VA. Hysterectomy and race. Obstet Gynecol 1993;82:757-64.
18. Lepine LA, Hillis SD, Marchbanks PA, Koonin LM, Morrow B, Kieke BA, et al. Hysterectomy surveillance-United States, 1980-1993. MMWR CDC Surveill Summ 1997;46:1-15.
19. Merrill RM, Feuer EJ. Risk-adjusted cancer-incidence rates (United States). Cancer Causes Control 1996;7:544-52.
20. Sherman ME, Carreon JD, Lacey JV Jr, Devesa SS. Impact of hysterectomy on endometrial carcinoma rates in the United States. J Natl Cancer Inst 2005;97:1700-2.
21. Wong CA, Jim MA, King J, Tom-Orme L, Henderson JA, Saraiya M, et al. Impact of hysterectomy and bilateral oophorectomy prevalence on rates of cervical, uterine, and ovarian cancer among American Indian and Alaska Native women, 1999-2004. Cancer Causes Control 2011;22:1681-9.
22. Lyon JL, Gardner JW. The rising frequency of hysterectomy: its effect on uterine cancer rates. Am J Epidemiol 1977;105:439-43.
23. Merrill RM. Impact of hysterectomy and bilateral oophorectomy on race-specific rates of corpus, cervical, and ovarian cancers in the United States. Ann Epidemiol 2006;16:880-7.
24. Lacey JV Jr, Chia VM, Rush BB, Carreon DJ, Richesson DA, Ioffe OB, et al. Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan. Int J Cancer 2012;131:1921-9.
25. Saraiya M, Lee NC, Blackman D, Smith M, Morrow B, McKenna MA. Self-reported Papanicolaou smears and hysterectomies among women in the United States. Obstet Gynecol 2001;98:269-78.
26. Gwinn ML, Lee NC, Rubin GL. Trends in the incidence of endometrial and ovarian cancers. MMWRCDC Surveill Summ 1986;35:23SS-7SS.
27. Merrill RM. Stat bite: trends in corpus uteri cancer incidence. J Natl Cancer Inst 1996;88:1019.
28. World Health Organization. International classification of diseases for oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
29. *Stat Database: Incidence - SEER 13 Regs Research Data, Nov. 2010 Sub (1992-2008), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, based on the November 2010 submission. [Accessed 2011 July 26].
30. Centers for Disease Control and Prevention (CDC). Behavioral risk factor surveillance system survey data. Atlanta, GA: U. S. Department of Health and Human Services, CDC. [Accessed 2011 Sept 9]. Available from: http://www.cdc.gov/brfss/technical-infodata/surveydata.htm; 2011.
31. Brett KM, Madans JH. Hysterectomy use: the correspondence between self-reports and hospital records. Am J Public Health 1994;84:1653-5.
32. Phipps AI, Buist DS. Validation of self-reported history of hysterectomy and oophorectomy among women in an integrated group practice setting. Menopause 2009;16:576-81.
33. Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of malignant mixed Mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004;96:70-4.
34. *Stat software. [Accessed 2011 Sept 1]. Available from: www.seer.cancer. gov/seerstat) version 7.0.7. 2012.
35. Devesa SS, Donaldson J, Fears T. Graphical presentation of trends in rates. Am J Epidemiol 1995;141:300-4.
36. Joinpoint Regression Program. Statistical Research and Applications Branch, National Cancer Institute. [Accessed 2012 Apr. 26]. Available from: http://surveillance.cancer.gov/joinpoint/. 2011.
37. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-51.
38. Merrill RM, Lyon JL, Wiggins C. Comparison of two methods based on cross-sectional data for correcting corpus uterine cancer incidence and probabilities. BMC Cancer 2001;1:13.
39. Bower JK, Schreiner PJ, Sternfeld B, Lewis CE. Black-White differences in hysterectomy prevalence: the CARDIA study. Am J Public Health 2009;99:300-7.
40. Powell LH, Meyer P, Weiss G, Matthews KA, Santoro N, Randolph JF Jr, et al. Ethnic differences in past hysterectomy for benign conditions. Womens Health Issues 2005;15:179-86.
41. Sabatino SA, Stewart SL, Wilson RJ. Racial and ethnic variations in the incidence of cancers of the uterine corpus, United States, 2001-2003. J Womens Health (Larchmt) 2009;18:285-94.
42. Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 2003;98:176-86.
43. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012;118:2338-66.
44. Centers for Disease Control and Prevention (CDC). Behavorial Risk Factor Surveillance System Summary Data Quality Reports. Atlanta, GA: U. S. Department of Health and Human Services, CDC. [Accessed 2012 May 9]. Available from: http://www.cdc.gov/brfss/technical-infodata/quality.htm; 2012.
45. Schneider KL, Clark MA, Rakowski W, Lapane KL. Evaluating the impact of non-response bias in the Behavioral Risk Factor Surveillance System (BRFSS). J Epidemiol Community Health 2012;66:290-5.
46. Centers for Disease Control and Prevention (CDC) NCHS. National hospital discharge survey. Hyattsville, MD: U. S. Department of Health and Human Services, CDC: 2012.
47. Centers for Disease Control and Prevention (CDC) NCHS. National Health and Nutrition Examination Survey. Hyattsville, MD: U. S. Department of Health and Human Services, CDC: 2012.
48. Centers for Disease Control and Prevention (CDC) NCHS. National health interview survey. Hyattsville, MD: U. S. Department of Health and Human Services, CDC: 2012.
49. Wun LM, Merrill RM, Feuer EJ. Estimating lifetime and age-conditional probabilities of developing cancer. Lifetime Data Anal 1998;4:169-86.